Impact of the motor complications of Parkinson's disease on the quality of life

被引:420
作者
Chapuis, S [1 ]
Ouchchane, L
Metz, O
Gerbaud, L
Durif, F
机构
[1] Ctr Hosp Vichy, Serv Neurol, Vichy, France
[2] Serv Epidemiol & Econ Sante, Clermont Ferrand, France
[3] Ctr Hosp Univ, Serv Neurol A, Clermont Ferrand, France
关键词
Parkinson's disease; quality of life; motor complications;
D O I
10.1002/mds.20279
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IVA and IVB and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia, led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients. (C) 2004 Movement Disorder Society.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 40 条
[1]  
Auquier P, 2002, REV NEUROL-FRANCE, V158, P41
[2]   THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
CARTER, WB ;
GILSON, BS .
MEDICAL CARE, 1981, 19 (08) :787-805
[3]  
BLIN J, 1998, NEUROLOGY, V38, P140
[4]   Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].
Block, G ;
Liss, C ;
Reines, S ;
Irr, J ;
Nibbelink, D ;
Aarli, J ;
Aguilar, M ;
Ahrens, S ;
Bakheit, A ;
Baumel, B ;
Bertoni, J ;
Capildeo, R ;
CastroCaldas, A ;
Deza, L ;
Donaldson, I ;
Franck, G ;
Fusillo, J ;
Gauthier, S ;
Gershanik, O ;
Granerus, AK ;
Hauser, RA ;
Hennessey, K ;
Hutton, JT ;
Joffe, R ;
Koller, W ;
Last, B ;
LeWitt, P ;
Mamoli, B ;
Manyam, B ;
Mark, M ;
Nakano, K ;
Nausieda, P ;
Otero, E ;
Paulson, G ;
Pinter, M ;
Reich, S ;
Rodnitzky, R ;
Sage, J ;
Sampaio, C ;
Smith, B ;
Teravainen, H ;
Tetrud, J ;
Tolosa, E ;
Ulm, G ;
Valesco, F .
EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27
[5]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[6]  
Calne S, 1996, Parkinsonism Relat Disord, V2, P55, DOI 10.1016/1353-8020(95)00026-7
[7]  
Clarke CE, 2002, NEUROLOGY, V58, pA469
[8]   Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life [J].
Damiano, AM ;
McGrath, MM ;
Willian, MK ;
Snyder, CF ;
LeWitt, PA ;
Reyes, PF ;
Richter, RR ;
Means, ED .
QUALITY OF LIFE RESEARCH, 2000, 9 (01) :87-100
[9]   Quality of life in patients with Parkinson's disease: Development of a questionnaire [J].
deBoer, AGEM ;
Wijker, W ;
Speelman, JD ;
deHaes, JCJM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) :70-74
[10]   Health-related quality of life and healthcare utilisation in patients with Parkinson's disease - Impact of motor fluctuations and dyskinesias [J].
Dodel, RC ;
Berger, K ;
Oertel, WH .
PHARMACOECONOMICS, 2001, 19 (10) :1013-1038